Navigation Links
Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
Date:8/4/2008

Agency Supports Amigal Move to Phase 3; Eligible for Accelerated Approval;

Final Global Regulatory Plan Expected by Year End

CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, announced today that it has successfully completed an End of Phase 2 meeting for Amigal(TM) with the U.S. Food and Drug Administration (FDA). The FDA indicated that the data from the completed Phase 2 clinical studies of Amigal support the start of Phase 3 development and agreed that Amigal meets the criteria to be considered for accelerated approval. The Agency further indicated that it is not opposed to the use of a surrogate primary endpoint, pending further discussion and final agreement on the Phase 3 trial design.

Amicus, along with its partner Shire Human Genetic Therapies, Inc. ("Shire"), is engaged in ongoing discussions with the FDA and the European Medicines Agency (EMEA) regarding plans for a global Phase 3 clinical development program for Amigal. In line with previous guidance, Amicus expects to complete these interactions in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate Phase 3 development of Amigal in the first half of 2009.

"We are very pleased with the outcome of the End of Phase 2 meeting with the FDA," said John F. Crowley, President and CEO of Amicus Therapeutics. "We look forward to continuing our work with the FDA and EMEA to design a global Phase 3 program for Amigal in Fabry disease."

The meeting followed the successful conduct of Phase 2 clinical studies in patients wit
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
2. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
3. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
4. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
5. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
11. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BUFFALO, N.Y. , Dec. 24, 2014 ... been dosed with KX2-361 at Roswell Park Cancer Institute. ... a small molecule drug that has shown potent inhibitory ... lines, including those that are resistant to Temozolomide (T98G), ... malignant glioma. In a well-established brain tumor mouse model, ...
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... Institute(R) Evidence Report Compares Effectiveness of CT Colonography ... The value of CT colonography, also called ... halting coverage of these procedures as a diagnostic ... Research findings from meta-analyses performed by ECRI Institute ...
... from MRI analysesROCHESTER, N.Y., March 12 VirtualScopics, ... provider of quantitative imaging for clinical trials, today ... company based in Laval, Quebec, has reached its ... for its cartilage repair device (BST-CarGel(R)) and will ...
Cached Medicine Technology:Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed 2Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed 3VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 2VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2
... the truth about deadliness of Alzheimer,s, report says , , ... medical officials often fail to record severe dementia as a ... This finding not only points to a lack of knowledge ... can be a deadly illness, it suggests that deaths due ...
... mom and preemie baby , , ... to get one live person out of this situation, and we ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20081209/SF50878 ... of neonatology at Lucile Packard Children,s Hospital at Stanford , ...
... ANTONIO, Dec. 9 The Texas office of Oaks ... II, a 35,000,square-foot medical office building at 3603 Paesanos ... just east of the intersection of Loop 1604 and,Northwest ... divides ownership of the building among the tenants, equity,investors ...
... plans, executive benefits and investment consulting services, announced that its award-winning ... — at just the touch of a button. , ... ... These new resources are in addition to Spanish language enrollment ...
... Biggest rise in cases and deaths coming in developing ... -- By 2010, cancer will be the leading killer ... than AIDS, malaria and tuberculosis combined. , Unless new ... with cancer by 2030, and 17 million cancer deaths ...
... pediatricians, Fatema Meah, M.D. became a doctor because she loves ... when she entered private practice, she was frustrated with how ... billing issues. Two months ago, she and her partner ... to return her attention to her patients -- Allied Pediatrics ...
Cached Medicine News:Health News:Dementia Often Missed as Cause of Death 2Health News:Dementia Often Missed as Cause of Death 3Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 2Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 3Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 4Health News:It's A Merry Christmas for Baby John After Mother Michelle's Life-Saving Transplant 5Health News:Oaks Development Group Closes on Third San Antonio Project 2Health News:Oaks Development Group Closes on Third San Antonio Project 3Health News: Newport Introduces More Resources for Spanish Speaking Plan Participants 2Health News:Cancer to Surpass Heart Disease as World's Leading Killer 2Health News:Cancer to Surpass Heart Disease as World's Leading Killer 3Health News:Cancer to Surpass Heart Disease as World's Leading Killer 4Health News:'Mega' Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain 2Health News:'Mega' Pediatric Group Allows Doctors to Focus on Patient Care as the Business Side of Private Practice Becomes More Difficult to Sustain 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: